As part of its ongoing expansion plans, ProAxsis Limited, the Belfast-based diagnostics company, is pleased to announce two new appointments within its commercial team.
Nina Morrison joins the company as Business Development Manager. Nina brings a wealth of field-based commercial experience to ProAxsis, having previously held roles at major pharmaceutical companies including Pfizer and Bayer Healthcare, with a focus on point-of-care testing and medical devices.
In addition, Jessica Robinson takes on the role of Sales & Marketing coordinator, based at the ProAxsis offices at Catalyst in Belfast. Jessica has just completed a BSc in International Business with Spanish at Queen’s University Belfast.
Dr David Ribeiro, CEO of ProAxsis, said: “In line with our stated strategy to expand our commercial operation, we believe that Nina and Jessica provide significant additional skills to the ProAxsis team and will enable enhanced promotion of our protease biomarker assays as well as our newly in-licensed assays from AstraZeneca and the University of Geneva. We’re delighted that they’ve both agreed to join the company.”
Nina Morrison, newly appointed Business Development Manager at ProAxsis, added: “I’m thrilled to be joining ProAxsis at such an exciting period of expansion for the company. With the recently announced in-licensing deals with both AstraZeneca and the University of Geneva, together with our existing assets of lab-based protease assays and NEATstik®, I can’t wait to get started and look forward to meeting existing and new customers at the earliest opportunity.”
Due to the growing nature of the company, we continue to look for high-quality candidates to join our team. Any new opportunities will be posted on our website – www.proaxsis.com
ProAxsis Limited is a commercial diagnostics company, based in Northern Ireland, and with a rapidly growing global client list of pharmaceutical companies and academic laboratories. The company has registered a CE Mark for activity-based immunoassays targeting Neutrophil Elastase (NE) and Proteinase 3, as biomarkers of lung infection and inflammation in chronic respiratory diseases such as COPD, cystic fibrosis and bronchiectasis.
This technology has been translated into a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels. Recently published data has shown that measuring active NE levels using NEATstik® enables identification of patients with airway bacterial infection and those patients at highest risk of suffering pulmonary exacerbations over the subsequent 12 months.
In addition to proteases, the company also has significant expertise in the measurement of other inflammatory biomarkers, including IL-6, IL-8 and TNF-alpha. Grant-funded R&D funded projects for a variety of targets remain a key area of focus.
Aside from the provision of assays, ProAxsis can offer sample analysis at its purpose-built laboratory facility in Belfast and is currently supporting a number of pharmaceutical company-sponsored Phase I, II and III clinical trials.
ProAxsis is a fully owned subsidiary of Netscientific plc, the international life sciences and sustainability technology investment and commercialisation Group.